Reversing the Angiogenic Switch with Photodynamic Therapy  by Arbiser, Jack L.
COMMENTARY
See related articles on page 634Reversing the Angiogenic Switch with
Photodynamic Therapy
Jack L Arbiser
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA
GonzaŁ lez et al (p. 634) demonstrates the utility of photodynamic
therapy in the treatment of vascular lesions in their manuscript
‘‘Photodynamic Therapy for Cutaneous ProliferativeVascular Tu-
mors in a Mouse Model’’. The ¢ndings illustrate two potential
ways of treating tumors. Photodynamic therapy has shown uti-
lity in the treatment of red tumors, while pulsed dye laser is e⁄-
cacious in the treatment of white lesions, such as hypertrophic
scars, keloids, and angio¢bromas.
The designation of red versus white tumors is a clinical desig-
nation. A red tumor is a tumor with leaky vessels, while a white
tumor is a tumor with nonleaky vessels. Folkman demonstrated
clinically that a red tumor could be converted to a white tumor
by the injection of saline, which increases the extravascular pres-
sure, forcing red blood cells back into the vessel (personal com-
munication). A common misperception among clinicians is that
red tumors are angiogenic and white tumors are nonangiogenic,
but recent data from our laboratory has shown that white tumors
can be highly angiogenic, yet not have leaky vessels (Arbiser et al,
1998).
Recently, the mechanism of red versus white tumors has been
elucidated. Most tumors produce vascular endothelial growth
factor (VEGF), which was isolated initially as a vascular perme-
ability factor (Senger et al, 1983). More recently, the presence of
two sets of angiopoietins, ang-1 and ang-2, has been associated
with vascular permeability (Suri et al, 1996; Maisonpierre et al,
1997). Ang-1 and ang-2 both bind to the tie-2 receptor, causing
activation of phosphoinositol-3 kinase, yet they have opposing
actions (Asahara et al, 1998). Ang-2 overexpression is associated
with highly aggressive liver and brain tumors, tumors which are
commonly red in appearance (Tanaka et al, 1999). In addition,
ang-2 is associated with the hemangioma-like lesions of verruga
peruana (Cerimele et al, in press). In contrast, overexpression of
ang-1 in vivo results in vessels that are resistant to vascular leak
(Maisonpierre et al, 1997; Thurston et al, 1999). The mechanism of
these opposing actions of ligands acting on the same receptor are
unknown.
Salvador et al demonstrate that photodynamic therapy is e⁄ca-
cious in the treatment of tumors in mice, which we derived by
introducingVEGF into MS1 immortalized endothelial cells. This
model is a classic example of a red tumor, and likely represents
the combined action of VEGF and angiopoetin-2 in vivo, result-
ing in the red tumor phenotype (Fig 1) (Arbiser et al, 2000).
What is the clinical utility of photodynamic therapy in the
treatment of vascular lesions? Three types of endothelial lesions
exist in humans. The most common form is hemangiomas of in-
fancy, which are red tumors that grow progressively, then regress.
The second class of tumors is malignant endothelial tumors,
which show continuous growth and invasion, and sometimes
metastatic growth. Tumors in this category include hemangioen-
dothelioma, Kaposiform hemangioendothelioma (Kasabach^
Merritt syndrome) and angiosarcoma. These tumors are
notoriously di⁄cult to treat. Finally, patients may have vascular
malformations, which may mimic hemangiomas clinically, but
which do not regress. All of these lesions are clinically red, and
likely result from vasodilation and vascular leakage. Photody-
namic therapy o¡ers a new therapeutic option for the treatment
of leaky tumors and malformations, based on the characteristic of
these tumors to leak and vasodilate, and thus accumulate photo-
active porphyrins (Hamblin et al, 2001).
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Figure1. Potential mechanism for vasodilation and accumulation
of photoactive porphyrins. Rac 1 (ras-related C3 botulinum toxin sub-
strate), cdc42 (cell division cycle gene 42), akt (Akr mouse thymoma onco-
gene), NFkB (nuclear factor kappa beta), tie-2 (tyrosin kinase in
endothelium).
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